• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
  • Understanding ALS
    • The Science, Explained
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • ALS Awareness Month:
      Behind the Breakthrough
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

Case Study: Unprecedented Biomarker Initiative Offers Optimism for People with ALS

Clinical biomarkers have been critical to achieving major breakthroughs and lowering the barriers to drug approval in a range of deadly diseases.

Currently, there are no reliable biomarkers to diagnose ALS early, track disease progression or group ALS patients with similar forms of the disease. After launching an Innovation Ecosystem largely focused on therapeutic targets, we turned our attention to biomarkers. In 2017, Target ALS brought together an unprecedented collaboration—11 pharma/biotech companies, four foundations, and over 20 academic experts—to identify, validate and further develop promising biomarker candidates on a pre-competitive basis.

Biomarkers can take many forms. Our collaboration’s first step was to fund a study that focused on proteins in either cerebrospinal fluid (liquid that bathes the spinal cord and brain) or blood. Our aim is to understand how they change during the course of the disease. Over the next five years, we aim to discover and validate the first set of biomarkers and clinical outcome measures in the history of the disease.

Usually, research like this takes years to become available to other scientists through peer-reviewed journals. In a historic first, the data from this new initiative will be shared immediately with the ALS research community worldwide. The field will benefit from the work and paving the way for accelerated biomarker development.

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting

Join us this ALS Awareness Month to discover the people, stories, and science accelerating progress in ALS research.

Name(Required)
Interests(Required)
Mark the options that best describe your interest in ALS